Lexaria Bioscience (LEXX) has released an update.
Lexaria Bioscience has announced preliminary findings from its second human pilot study, indicating that its DehydraTECH-processed Rybelsus medication may enhance overall absorption when taken with food. Although the sample size was small and results were not statistically significant, there was an average 18.8% increase in semaglutide levels over the course of the study compared to the non-processed version. The study compared the absorption of the drug in tablet and capsule forms when taken in a fed state, against the manufacturer’s recommendation of administration on an empty stomach.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
